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ABSTRACT 
 
QUSH, ABEER, SULEIMAN, Masters of Science : June : 2019, Biomedical Sciences 
Title: Forecasting The Blood Stock Required During World Cup Events Qatar 2022 , Prepositions, 
and Articles 
Supervisor of Project: Dr. Layla, Yehya, Kamareddine. 
Background: In four years from now, Qatar will host the 2022 World Cup competition 
which requires high level of preparedness and readiness in different sectors including 
health care.  Among different sub-sections of health, the blood bank and the Blood Donor 
Center will have a major role in this event especially in case of unforeseen incidences. 
Accordingly, a proper assessment of the current blood resource availability and a 
prediction of future blood needs helps in overcoming any obstacle that could be faced 
during the event. Objectives: (1) Highlight the process of the blood supply chain, with a 
detailed delineation of the needed amount of blood components for both routine and 
emergency situations services, and outline the proper measures taken to deliver the safest 
and most appropriate blood units and reduce wastage of blood component. (2) Assess the 
current standing of the Blood Donor Center and corresponding units in Qatar. (3) Develop 
a forecast model that predicts the number of blood donors in the next four years as a 
method to evaluate the readiness of the Blood Donor facility to host the world cup event. 
(4) Explore the potential challenges that could be faced when meeting the benchmark of 
donation and established an action plan to overcome these anticipated challenges. 
Materials and Methods: Both qualitative (interviews) and a quantitative (data collection 
and analysis) approaches have been implemented in our study. We also established a time 
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series forecast model using Autoregressive Integrated Moving Average (ARIMA). 
Results: The number of donors in the next four years, which is predicted to increase by 
26%, will not be able to get accommodated in the current Blood Donor Center facility. 
Therefore, the established blood stock benchmark will not be met despite that the Center 
and its corresponding units are fully equipped with high standard equipment and follow 
international guidelines in the process of blood withdrawal. Conclusion: Infrastructure 
improvements and logistics support for Hamad Medical Corporation Blood Donor Center 
are required to support the continuously increasing numbers of blood donors for daily 
demand and during mega events. 
 
Key words: Forecasting, demand, 2022 World Cup, Blood Donor Center, Donor Marker 
Testing Unit, Component Processing Unit, Blood Bank, Infrastructure, Logistics, 
Challenges and Awareness. 
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CHAPTER 1: INTRODUCTION 
Qatar is expecting around 1.3 million football fans during the World Cup 
competition. This event requires proper preparedness and readiness in different sectors 
including the health care. Among different sub-sections of health, the blood bank and 
Blood Donor Center (BDC) will have a major role in case of unforeseen incidences that 
might happen during this event. Therefore, the blood bank should have adequate blood 
stocks and should stay alerted to any risk that could occur in case of any emergency. A 
proper assessment of current blood resource availability, stock management, and a 
prediction of future blood is needed to provide quality services in this sector and help in 
overcoming any obstacle that could be faced during the event. 
1.1.Research questions 
(i) What is the expected percentage increase in the number of blood donors in four 
years from now? 
(ii) Is the Blood Donor Center at Hamad Medical Corporation prepared to 
accommodate a huge number of donors? 
(iii)  What are the possible challenges that could be faced by the Blood Center as a 
result of the anticipated increase in the number of donors?  
1.2.Research objectives 
This study encloses four main objectives: First, to outline the detailed processes of blood 
collection, processing, screening and storage at the Hamad Medical Corporation Blood 
Donor Center (HMC-BDC), delineate the needed amount of blood components for both 
routine and emergency situations services, determine the implicated measures to deliver 
the safest and most appropriate blood unit, and identify the followed practices to reduce 
  
   
2 
 
wastage of blood and blood components. Second, to assess the current standing of blood 
stocks in the blood bank and questions self-sufficiency and ability to meet blood stock 
demands during the 2022 event. Third, to develop a forecast model that predicts the number 
of donors in the next 4 years as a method to evaluate the readiness of the HMC-BDC facility 
to host the world cup 2022 event. Finally, to explore the potential challenges and obstacles 
that could be faced to meet the benchmark of donation and provide recommendations and 
an action plan to overcome anticipated emerging challenges. 
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CHAPTER 2: LITERATURE REVIEW 
Since 1930 until nowadays, the Fédération Internationale de Football Association 
(FIFA) World Cup competition is considered the biggest sport event in the world. This 
event encloses 208 members of FIFA associations competing together to win the World 
Cup every four years [1]. In such mega events usually, the hosting country has to meet 
certain preparation standards in different aspects including infrastructure (stadiums, hotels, 
transport, and communication services) [2]. When Russia hosted the 2018 World Cup 
event, national and urban improvement was its primary target [3, 4]. Eleven cities across 
Russia welcomed more than a million international spectators [5]. Around ninety per cent 
of the initial investment was planned to develop the infrastructure of cities and 
communities. Lots of effort also extended beyond the sport stadia and where mainly 
directed towards improving the cities around Russia, as such mega-events are not only 
organized for entertainment purposes but also contribute to advancement of many national 
programs, mainly those based on economical foundations [6]. Such events develop nations 
and promote investment, therefore creating better life style for millions of people [4]. 
Several reports issued by different consulting companies outlined such advantages of 
hosting mega-events [7-9]. Organizing the World Cup event in South Africa in 2010 for 
example reduced poverty and encouraged public health awareness. [10]. Likewise, the 
2014 World Cup event and the 2016 summer games organized in Brazil aimed to develop 
urban transport and advancement of nearby neighborhood in Rio de Janeiro [11]. It is worth 
mentioning here that global media helps the sports industry a lot and influences decision-
making. The economy of countries hosting mega event vastly increases usually from 
tourism and advertisement based revenues [12]. The revenues generated from the 1994 
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World Cup in the United States, for instance, exceeded four billion dollars, flourishing 
tourism in the States at the time [13]. 
In December 2010, and on that cold Zurich night, the FIFA organizers surprised 
the world by granting the small Persian Gulf State of Qatar the opportunity to host the 2022 
World Cup event [14]. Although Qatar is a small country, populated by around 300,000 
citizens only, it is considered one of the richest per capita states globally. Qatar, the 
sovereign Arab State, has gained the majority of the FIFA executive committee votes, 
turning the dream of hosting the ‘royal football league’ into reality. Accordingly, Qatar 
became the first Middle Eastern Islamic country that merited the privilege of hosting this 
global sport event. The outcomes of this event, which are aligned with Qatar’s 2030 vision,  
will place Qatar in universal recognition, cultural exposure, and at the center of business 
activities around the world [15]. Today, Qatar’s road map is heading towards an 
international center for sport excellences, that creates a long lasting legacy for Qatar in the 
Middle East, Asia and the world [14]. For the past several years, Qatar has paid particular 
attention to sports at the national, regional and international levels, as it believes in the 
ability of sports to bridge among nations worldwide. World cup is not the first experience 
for Qatar to host a sport event. Qatar has previously hosted the 2006 Asian Olympic Games 
and the 2015 World Handball Cup events successfully [16]. Qatar continues its path 
towards organizing successful sporting event and establishing a state-of-art infrastructure 
by governmental, quasi-governmental and private companies [15]. 
Qatar is expecting around 1.3 million visitors including fans, spectators and media 
representatives to attend the World Cup event [17]. To be able to successfully host that 
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number of visitors, Qatar should be at a high level of preparedness in all sectors. As part 
of its preparations, Qatar plans to invest more than $200 billion on constructions and 
infrastructures. The plan includes building a new airport, public transportation routes such 
as a metro system, high-speed rail network, and 40,000 more hotel rooms and residential 
buildings in addition to the currently available ones[18,19]. Moreover, Qatar is also 
constructing air-conditioned stadiums with breathtaking designs, and many entertainment 
venues to meet the FIFA requirements. Besides that, Qatar and through its public health 
institution, is working on providing an advanced health care system that offers high quality 
services based on national health policies that integrate specific standards of economical, 
social, financial, administrative and technical aspects [20]. The 2022 Local Organizing 
Committee (LOC) is currently working on meeting the international standards for health 
and medical services with particular focus on health care facilities, emergency medicine 
provisions and specific medical systems, including staffing, infrastructure and anti-doping 
services [2].  
Among different health care services, blood donation is of a primary concern to the 
LOC members because blood serves as a major lifesaving element in cases of any medical 
emergencies or complication. In the blood donation center, several blood supply chain 
activities routinely occur including (1) blood collection from donors (2) blood processing 
(3) distribution of blood components to all hospitals and healthcare institutions and (4) 
blood disposal. Appropriate planning and controlling of these activities is required to avoid 
any stock-out or outdate of blood components [21]. 
The management team at the Blood Center encourages people to participate in 
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humanitarian practices in cases of emergency or when blood stocks are decreases. The team 
members reach out to regular donors and other members of the population in several ways 
including campaigns, phone calls, sending emails, text messages, media (TV or radio) and 
through social networks (Facebook, Twitter, etc.). The collection process can be carried 
out either in public or in private areas of public and private institutions, companies and 
hospitals [21, 22]. This encouraging role of the management team members is very 
important because in some countries, voluntary donation is not considered a regular ritual. 
Blood services vary between countries and are usually either centralized or decentralized. 
The choice between either services is related to many factors including building, 
infrastructure, transportation facilities, and the availability of skillful and trained staff. 
Many developed countries have implemented the centralized model, which aligns better 
with their national management structure and policies [23]. 
Each country has its own National blood policy that describes the principles and strategies 
of the blood supply chain from donor recruitment, to donor selection and deferral, to 
transfusion transmitted infection (TTI) blood screening, to reactive screening test results 
confirmation, to donor notification of positive TTI test results, to readings post-donation 
support that include counselling and referral [24]. The general blood collection process is 
summarized below. 
2.1. Blood collection  
 Whole blood is generally collected from donors with a minimum interval between 
one donation and the other of 12 weeks for males and 16 weeks for females. Platelets and 
plasma collections happens more frequently however and within shorten intervals [25]. 
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2.1.1 Donor selection 
Donor selection is an important building block of the blood collection process. 
Many considerations are taken into account during the donor selection process including: 
(1) protecting the donors from any adverse post donation effects (2) protecting the 
recipients and reducing the risk of TTIs (3) avoiding resources wastage that arises from 
donors that don’t comply with donation guidelines [26]. Recent reports from the World 
Health Organization Global Blood Safety Database on Blood Safety show that 92 million 
blood donations from 164 countries are collected yearly, 1.6 million units of which are 
wasted due to positive detection of the infectious markers of TTI, HIV, hepatitis B, 
hepatitis C and syphilis, with at least 13 million deferral donors because of anemia [27]. 
Collectively, these aforementioned considerations necessitates an effective blood donor 
selection process [26]. 
The health status of the donors is another crucial factor that is considered during the 
selection process. The donor should be in a good health on the day of the donation to avoid 
any health related complications during the collection process [26]. Donors should eat a 
light meal before donating blood to avoid fainting, and a heavy meal should be avoided 
prior to donation to avoid the detection of lipid plasma, a condition that necessitates 
discarding the collected plasma [28]. 
2.1.2 Donor reception and registration 
All potential blood donors that meet the general acceptance criteria of age and 
health conditions should be registered in the Blood Donation Center System apart from 
whether they are subsequently admitted to donate blood or not. During the registration 
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process, donors provide basic identification information including their full name, 
demographic location and contact details. After registration, each donor be given a unique 
identifier (donor card) and a donation number that will be attached to the questionnaire, to 
the primary and secondary blood bags and to the sample tubes. In any donation process, 
education documentation and a questionnaire should be given for regular and new donors 
and should be completed during the registration process [26]. 
2.1.3  Medical interview 
All donors will be subjected to a medical interview to determine their eligibility to 
continue the process of donation. Such questionnaires, which are in the form of a one-on-
one interview, generally assess the health condition, travel history, medical record and risk 
of having TTI infection [26]. Privacy and confidentiality are highly considered during these 
interviews, to assure that the donor is comfortable to answer personal questions. 
Overcoming the language barrier is also considered while conducting this interview, so 
that the donor can understand the questions clearly and answer properly. Along this 
interview process, a written consent is obtained from the donor, approving blood testing 
for TTI, use of blood transfusion, quality assurance or research purposes, and confirming 
the validity of the information provided [26]. 
Qualified staff like nurses/transfusion medicine physician perform the evaluation of the 
medical questionnaire only. The eligibility criteria for whole blood donation varies among 
countries. Many countries implement the American Association of Blood Banks (AABB) 
and the Council of Europe (CE) guidelines for the regulatory requirements of blood banks, 
transfusion services, and other immunohematologic practices. This variation in the 
eligibility policies and in the criteria of assessment explains the discrepancy in the deferral 
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rates between blood institutions. In 2010 for example, percentage of the deferral among 
European countries, USA and Canada ranged between 1.4% and 25% [29]. In general, 
differences in eligibility and assessment criteria can be related to different factors 
including; severe need of blood, the financial standing of the Center, the demographics of 
the country, the spread of endemic diseases in certain areas, drug use, sexual history, 
residential history and others. Some countries decide on blood donations eligibility based 
on epidemiological criteria only while others request additional serological tests [30]. In 
Canada for instance, although 60% of Canadians are eligible to donate blood, [31, 32] the 
percentage of donation is less than 4% every year due to critical deferral criteria followed 
the country [32].  
2.1.4 Physical Examination 
After the medical interview and before donating blood, the donor also undergoes a 
physical examination that checks for remarkable signs and symptoms of illness or 
conditions that will result in their discontinuation of blood donation. In most countries, the 
eligibility of blood donation is 18 years and above. Some countries, however, allow 16-17 
year-old participants if they pass the medical examination tests and fill out the consent 
form. The volume of whole blood donated should not exceed 13% of total blood volume; 
the weight of the donor should be at least 50 kilograms to donate 450 ml ± (10%) of blood. 
Similarly, the total volume of donated plasma, platelets and red cells collected should not 
exceed 13% of total blood volume and the maximum extracorporeal blood volume should 
not exceed 15% of the donor's total blood volume for apheresis procedures. Gross obesity 
could be a reason for deferral due to difficulties in reaching the veins of the donor. The 
international and national blood donation guidelines also indicate the hemoglobin levels 
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should be at least 12.5 g/dl in females and 13.5 g/dl in males. Other indicators of good 
health status include a regular pulse rate (60–100 per minute), oral temperature (less than 
or equal to 37.50C), systolic pressure (120–129 mmHg), and diastolic pressure (80–89 
mmHg) [26].  
A recent study showed a significant variation in the physical examination criteria 
implemented by different countries. In the United States, where the majority of Americans 
are obese, the 50-kg weight requirement can be easily met in the Indian population, with a 
45 kg weight is considered acceptable [30]. Donors that don’t pass the physical 
examination test, and therefore do not meet the eligibility criteria for donation, or are 
deferred due to any other reason, are usually prohibited from donation for either a 
temporary or a permanent period after a proper given clarification and advice for medical 
follow up [26].  
2.1.5 Donor Phlebotomy 
In blood donation, safety is a major concern for both the donor and the recipient. 
Reducing the likelihood of contamination of donated blood unit by skin flora from the 
donor's arm is a major consideration when collecting blood. Pathogens can multiply during 
storage, leading to fatal complications [33, 34] . Accordingly, effective antiseptics are used 
prior to withdrawing blood. Applying a combination of 2% chlorhexidine gluconate and 
70% isopropyl alcohol for 30 seconds on the donor’s arm, followed by 30 seconds drying 
time, is a frequently adopted sterilization practice in blood donation [35, 36]. 
Blood is usually collected for either whole blood usage or for apheresis. Plasmapheresis 
consume at least 45 minutes, and more than three hours for plateletpheresis compared to 
the 15 minutes time need for whole blood donation [37]. In apheresis, a fixed quantity of 
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blood is collected in an extracorporeal volume (ECV) bolus and the needed components 
(e.g. Platelets) are separated and collected in the collection bag, while other components 
(e.g. red blood cells, leucocytes and plasma) are returned back to the donor [38]. 
Post blood withdrawal, the donor should relax for a few minutes on the bed before leaving 
the donation room, and should receive some refreshments to re-set his normal balance 
before leaving the Blood Donation Center [39].  
As for the collected blood, whole blood should be held in an environment that allows it to 
gradually cool down to 20 0C to 24 0C before beginning with processing. Blood bags will 
be further sent to the laboratory for processing and serological testing. Universal safety 
precautions should be always followed when handling blood specimens as all reagents and 
patient samples are considered potentially infectious [40]. 
2.2 Blood processing and screening 
Collected blood samples are sent to the Blood Center, to undergo serological 
testing. In parallel, the rest of the blood bags are sent to the Component Processing Units 
for blood separation into components through a complex process [39], [41-43]. Any 
discrepancy between the blood bag and the collected specimen will be further investigated 
and resolved prior to testing and processing of units.  
2.2.1.  Immunohematological testing 
Currently, the International Society of Blood Transfusion includes a list of 33 blood 
group systems representing over 300 antigens. The most important system in transfusion 
and transplantation is the ABO system and the Rhesus-system, which contain only five 
important defined blood group antigens out of 50, in addition to the Kell blood group 
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system that is classified as the third most potent immunogenic antigen after ABO and Rh 
system. Common Rhesus and Kell antigens are also frequently tested for in blood donors 
because of their clinical relevance.  
Thus, common immunohematological testing includes determining the ABO group, Rh 
Type and any unexpected antibodies against red blood cell antigens of the donor [44, 45]. 
2.2.2. Blood components production 
From each donor, one blood unit of 450 ml of blood is collected and processed to 
obtain the needed blood constituent such as red blood cells (RBCs), platelets, plasma and 
other products. Thirty different products can be obtained from blood processing. Thus, 
several patients can benefit from one donation [46, 47]. Most common blood components 
are packed red blood cells (PRBC), washed PRBC, leukoreduced PRBC and pooled or 
aphaeresis platelets; while plasma products such as Fresh frozen plasma (FFP) or 
cryoprecipitate antihemophilic factor (AHF), are less common [48]. Each of these products 
have a different shelf life [46, 47]. 
Blood components are generally used for different medical purposes. Red cells, FFP, 
platelets are used for example for patients undergoing surgery or in case of major blood 
loss due to accidents [49]. Packed red cells (leukocyte free) are, in turn, used for premature 
infants. FFP are also used for treating patients with burns and bleeding injuries, particularly 
those having deficiencies in multiple coagulation factor due to liver disorders or 
disseminated intravascular coagulation [50]. In order to be used for correction of inherited 
and acquired coagulopathies the Cryoprecipitate AHF is usually produced by slow thawing 
of FFP. Cryoprecipitate, which is rich in factor VIII, fibrinogen, fibronectin, von 
Willebrand's factor (vWF) and factor XIII can be also used for correction. Beside the chief 
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role of platelets in reducing bleeding, it is commonly used for cancer patients as well [47]. 
Since 1960 blood components were prepared by separated blood products from one unit of 
whole blood through a refrigerated centrifuge [51]. Red Blood Cells Leukocytes Reduced 
(PRBCs) are either be prepared automatically or manually by centrifugation and filtration 
of whole blood unit. Saline Adenine Glucose Mannitol solution (SAGM) is further added 
to extend the shelf life of RBC for 42 days, with increased functional capability and 
increased level of ATP in red blood cells [38]. After the RBCs bag are mixed with SAGM, 
they will be ready for the next step which is filtration and storage.  
FFP is, in turn, is prepared from whole blood by a single‑step heavy spin centrifugation 
[51]. Liquid Plasma and Plasma Frozen within 24 Hours after phlebotomy (FP24) are also 
prepared from a whole blood. Also, cryopreciptated AHF is prepared by separating the cold 
insoluble portions from FFP one-hour post preparation [40, 52]. Platelets can be obtained 
by two methods, either harvesting them from whole blood unit or from single donor 
“platelet apheresis”. In the first method, four to six interim platelet units are pooled and 
filtered with a platelet pooling set to create a final pooled platelets product. In the second 
method, a special machine that separates the blood cells during the collection process is 
used. Platelets are then collected in bags while other blood components (e.g. red blood 
cells, leucocytes and plasma) are returned to the donor. Agitation is required during the 
platelet units storage process to prevent clumping of cells [48]. 
2.2.3.  Blood screening 
Over the past three decades, different types of screening tests have been designed 
to detect antibodies, antigens or the nucleic acid of the infectious agent in blood. Many of 
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these tests have limited usages. Deciding on which test to implement is usually based on 
several factors like sensitivity, specificity, cost and ease of application. 
In the blood bank, two main types of tests are generally used for blood screening: (1) Immunoassays 
which include [Enzyme immunoassays, Chemiluminescent immunoassays, Haemagglutination 
/particle agglutination assays and Rapid/simple single-use assays (rapid tests)] and (2) Nucleic acid 
amplification technology (NAT) assays. In today’s practices, whole blood and apheresis are 
generally screened for HIV-1 and HIV-2 antigen/antibody, hepatitis B surface antigen (HBsAg), 
hepatitis B core antibody(anti-HBc), hepatitis C antibodies (anti-HCV) antibodies and specific 
treponemal antibodies infectious markers. Screening for malaria antibodies or Chagas disease 
might also apply depending on local epidemiological evidence [53]. Serological screening of blood 
products for hepatitis B virus (HBV), HBsAg , anti-HBc, hepatitis C virus (HCV), human 
immunodeficiency virus (HIV1/2), cytomegalovirus (CMV) and syphilis started in period ranging 
from 1970 to 1990s [44]. In 1995, the World Health Organization (WHO) and the National 
Institutes of Health (NIH) recommended to screen every donor for different infectious test such as 
HIV, hepatitis B and C, malaria, and syphilis [54]. In 2004, and due to increased awareness of 
clinical complications of TTI, AABB, and in corporation with the Food and Drug Administration 
(FDA), issued standards serological tests to detect risk of TTI in the donor’s blood [55]. 
Although introducing hepatitis B surface antigen (HbsAg) as a routine screening test 
decreased the risk of TTI of HBV in the early 1970s, the test had still some limitation in 
detecting the presence of HBV during the 'window period' [56]. Therefore, the combination 
both serological testing and NAT has considerably reduced the risk of viral transmission 
by blood transfusion [57-59] 
NAT testing is a new trending screening test technology used to detect HIV and HCV. Its 
advantage over other screening methods lies in its sensitivity and specificity of detecting 
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viral nucleic acids, especially in early stage of infection. Therefore, this technology 
contributes to narrowing the pre-seroconversion window period and can detect false 
positive reactive tests [60]. A major disadvantage of NAT, however, is that it is unable to 
detect low level viremia [61]. 
In Late 1990 and early 2000, the NAT approach was introduced in developed countries 
(primary Germany). Today, about 33 countries in the world rely on NAT for HIV detection, 
and approximately 27 countries rely on it for HBV identification [62]. Applying NAT in 
the UK for blood screening, for example, reduced the risk of HCV infection by 95% and 
HIV infection by 10% [63].  
2.2.4.  Pathogen inactivation 
The risk of pathogen transmission has been recently reduced by the implementation 
of several pathogen inactivation strategies such as filters and the Mirasol Pathogen 
Reduction Technology (PRT) System which includes Riboflavin (vitamin B2) with UV 
light. Such system work on stopping the replication and/or transcription of nucleic acids, 
thus inactivating the microorganism. However, this system is not effective with cells that 
lack nucleic acid such as platelets and red blood cells [64-66]. Likewise, donor leukocytes 
should be also inactivated. These strategies enclose “nanofilters” that eliminate viruses 
having a protein membrane, while those with a lipid envelope virus cannot be eliminated. 
Also, aseptic membrane filtration (0.22 nm) can be used to eliminate micro‑organisms 
before filling the blood in containers [67, 68]. 
Collectively, all these practices including deferral criteria, donor screening, serologic and 
nucleic acid testing (pathogen inactivation) aid in providing safer blood for transfusion. 
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Unfortunately, poor financial support in many health service organizations, especially in 
developing countries, remains a major obstacle in implementing these screening 
approaches and reducing the risk of pathogen transmission.  
2.2.5. Blood Storage 
Because blood components are perishable, a synchronized processing of blood starting 
with immunohematological testing, blood screening, blood components segregation and 
reaching storage is essential [69].  
According to the FDA standards, a novel implementation in blood storage technology has 
been introduced in the United States where RBCs are now being stored up to 42 days [70]. 
Due to the novel usage of additive solutions and validation criteria, the shelf life of RBCs 
has been also extended in Europe and is now considered to be 49 days [71-73]. 
The storage of each blood components follows specific guidelines: 
(1) PRBCs is generally stored at 1-6 0C for 42 days with SAGM additive solution, up to 
21 days with citrate phosphate dextrose (CPD) anticoagulant preservative; or for 35 
days with citrate phosphate dextrose adenine (CPDA1). 
(2) Liquid Plasma is stored at 2-6 0C for 26 days. 
(3) FP24 is stored at -180C or colder for one year starting on the first day of collection. 
(4) FFP and Cryoprecipitated AHF are stored at -180C or colder for one year from the day 
of collection. 
(5) Interim Platelet Unit is stored at 20-240C for 24 hours after separation from whole 
blood. 
  
   
17 
 
(6) Pooled platelets leukocytes reduced and apheresis platelets are stored at 20-240C for 5 
days with constant agitation, and 7 days if platelet additive solution (PAS) is used [40, 
52].  
Separating and marking screened reactive units from the quarantined ones, and securely 
storing quarantined stocks for their disposal or later usage for quality assurance or research 
purposes is also a critical element in the storage process [53].  
Blood bank employees must continuously check the quality of blood components such as 
Red Blood Cells Leukocytes Reduced, Cryoprecipitated AHF, FFP and platelet 
concentrates to assure effective, and safe blood product with the lowest risk possible. Blood 
quality assessments are generally based on the AABB criteria that requires specific 
monitoring for each type of blood [74].  
2.3 Blood distribution to hospitals and health care institutions 
In many countries, Community Blood Centers are responsible for blood collection, 
blood processing into components, and finally blood distribution to blood banks and other 
hospitals and laboratories [21, 75]. Many countries have centralized agencies like the 
Canadian Blood Services in Canada and the American Association of Blood Banks in US. 
These agencies control the process of blood supply with other regional Blood Centers. 
Regional Blood Centers are usually responsible for collecting, processing and dispatching 
blood to different facilities in their regions. In the event of low blood inventories as in 
emergency situations, the blood bank will reduce dispatching blood units to hospitals and 
will only allocate the available blood for urgent requests. Such reductional practice usually 
relies on the policy of the blood bank inventory [73]. 
Validated shipping containers are used only for the purpose of transporting blood 
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components between different storage locations [76]. These containers are used to maintain 
the proper transport temperature that is appropriate for the blood component. RBCs and 
Plasma Frozen products including PF24, FFP, Cryoprecipitated AHF, and Plasma 
Cryoprecipitated must be transported at 1 to 10 0C, while platelets should be transported at 
20 to 24 0C. The maximum number of blood component units that should be transported 
and packaged in one transport box and the number of ice packs needed in for transportation 
generally follows the manufacture’s recommendations [40, 52]. 
Several factors should be evaluated during the shipments process including the shipping 
transit time, mode of transport, climatic conditions to which the container may have been 
exposed, presence of residual wet or dry ice upon receipt, and the gross appearance of the 
blood components received. Any deviation from routine shipping or component conditions 
should be documented and reported to the shipping facility. Similar evaluation of blood 
components transported between Blood Centers and hospitals should be performed by the 
receiving facility. Once the blood component arrives to the blood bank, and after 
crossmatching them for further blood type assurance, some units will be reserved as an 
assigned inventory. These assigned inventory units will remain until they are requested for 
transfusion or will be returned back as unassigned inventory for future utilizations [77]. 
All expired and spoiled units will be considered as wastage and eventually disposed [75]. 
2.4 Blood disposal 
Disposal of blood products occur either during the processing of blood components 
and screening of blood samples or after blood distribution. This indicates that wastage can 
happen in any stage across the supply chain process [78]. A study conducted by Stanger et 
al. showed that the wastage in hospitals is notably higher the wastage in Donor Centers in 
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the United Kingdom and Germany [79]. Wastage of blood products can be due to several 
factors including expired blood units, clotted blood, broken bag, broken seals, returned 
unused RBCs bags for the blood bank after 30 min or failure of the blood unit after Internal 
Quality Control (IQC) assessment. Blood components that require disposal from the 
hospital or any medical service will be sent to the Blood Center by incineration [21, 40, 
80]. A study conducted in all hospitals in Qazvin Iran, including teaching, social welfare, 
private, charity, and military hospitals illustrated three major causes of blood and blood 
component wastage including outdated units, patient hospital shortage of using these 
products and unused blood product [80, 81]. 
As for the “30-minute rule” and related guidelines for blood transfusion, many countries, 
like UK for example, advise to dispose RBC units that are not monitored for temperature 
storage for more than 30 min, because once RBC units warms up, the risk of bacterial 
proliferation increase over time [82]. 
It is worth mentioning here that because of the high demand of blood and blood 
components which is often unpredictable, blood and blood components are rarely out of 
date. However, outdating and wastage of blood and blood products can still significantly 
decrease if there is no proper adherence to guidelines [69, 79, 83, 84]. Undoubtedly, the 
consumption of blood units before they expire in treatment will avoid paying dispensable 
costs. The balance between consumption and wastage requires improving blood inventory 
management practices because having unnecessary stocks leads to unnecessary costs and 
wasting blood units also means wasting the donor’s time and effort. Good inventory 
management practices require sufficient stock to cover the demand and at the same time 
reduce the expiry period [78, 85, 86]. 
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Blood, blood products or contaminated materials should be disposed in a safe manner 
following specific policies of the donation center. There are several ways to dispose blood, 
including onsite treatment by heat sterilization, incineration and chemical treatment, or 
collecting the discarded materials in secure areas or off-sites disposed through specialized 
contractors [23].  
Effective performance of Blood Center starts with accurate forecasting of future needs of 
blood and blood constituents. Information provided about the past use of blood and blood 
components by hospitals and the number of available donors on weekly or monthly basis, 
is usually important to help the Blood Center in decision making. These decisions can be 
strategic to improve the proper use of existing resources, to promote an increase in the 
number of donors, to implement any needed expanding in the infrastructure, and to 
consequently guarantee that all demands will be met in disastrous or situations mega-events 
[21]. Having that said, the blood bank should be on a high level of preparation on daily 
basis, in cases of natural or man-made disasters, or where hosting mega events, which 
require stockpile of blood. For the World Cup event for example, the hosting country 
should be readily alert to respond to any risk that could occur, especially among the crowds, 
in addition to its regular readiness, to meet the patient demands every day. So, it is 
particularly useful for the blood bank to use guidelines that has been previously established 
by blood management committees for successful emergency operations procedures. These 
guidelines can help in building mock scenarios that are not encountered in everyday 
workplace. Retrospective review of previous disaster experience greatly helps as well. 
Developing a disaster plan is also needed to provide further knowledge on the quantity of 
blood required, availability of blood components, routes of communication and mobilized 
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hospital staff [87]. 
Several challenges usually arise in planning and controlling such events. Some of which 
falls in the context of deciding on how to handle the process of blood donation and stock 
management [88]. Notably, cost is considered a focal point and a driving force of all such 
operation management activities.  
Most countries face challenges in achieving self-sufficiency in blood components and 
blood types and struggle to meet current and future population needs and to balance 
between increased production and optimized utilization. Maintaining a high quality and 
safe blood products is one of the faced obstacles. Other obstacles also fall in the category 
of the risk of transfusion-transmitted pathogens, low percentage of blood donors, 
increasing demands, poor blood supply systems. This will eventually results in blood 
shortages, unsafe blood products and questionable blood service practices [89] .  
Like all countries, Qatar is also concerned with these obstacles and is currently working on 
overcoming them before 2022. A proper understanding of the current available and the 
future needed blood resources is a must.  
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CHAPTER 3: MATERIALS AND METHODS 
3.1. Ethical compliance  
 The proposal of this study has been submitted to Hamad Medical Corporation 
through the ABHATH –MRC’s online research system. The presented study documents 
have been assessed initially by assigned reviewers and was then passed down to the 
scientific review committee by Medical Research Center (MRC). The submitted proposal 
has been categorized as a quality improvement study and therefore the study got exempted 
from IRB review by MRC. The only needed ethical compliance was an approval from the 
Department of Laboratory Medicine and Pathology (DLMP). Accordingly, this approval 
has been obtained from the Transfusion Medicine Department- DLMP and is attached at 
the ended of this capstone exhibition in the Appendix section. 
3.2. Data collection 
Our study has been conducted in the BDC-Department of Transfusion Medicine at 
Hamad General hospital which is located on Hamad Medical Corporation campus. In this 
study, both qualitative and quantitative approaches have been implemented.  
3.2.1. Qualitative approach 
For the qualitative part of our study, semi-structured interviews have been 
conducted. The interviewed Head Nurse of the HMC-BDC has provided adequate 
information about registration requirement, medical interview, physical examination 
acceptance criteria, staffing schedules and other services provided at the Center. 
Information about the kind of blood bags and types of donors was also provided by the 
Head Nurse in the Center. The Head of Transfusion Medicine and Blood Banks provided 
information related to the blood wastage, misuse practices and pathogen inactivation 
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techniques. The conducted interview with the Medical Manager, in turn, provided 
information related to the working system in the Center, the arrangement of campaigns 
among the year, the announcement methods used in cases of emergency, the challenges 
and obstacles faced during the blood donation process, and the limitations encountered by 
the blood bank to meet the donation benchmark. 
3.2.2. Quantitative approach 
3.2.2.1.Data collection from interview and site visits 
For the quantitative part of the study, one data set have been collected from semi-
structured interviews and from direct site visit observations. Within this set, data has been 
categorized into:  
(i) Number of workers (nurses, clerks and drivers) in the BDC and number of 
technologists in the Component Processing Units and in the Donor Marker Testing 
Unit. 
(ii) Assets available in the BDC (equipment, beds and cars); assets available in 
Component Processing Units and in the Donor Marker Testing Unit 
(instrumentation, Centrifuges, Mirsol-pathogen reduction system, extractors 
among others). 
(iii) Time frame (working hours, number of shifts, allocated time for each step in the 
process). 
(iv) Number of campaigns organized every day. 
(v) Blood inventory management (number of blood bags collected from each 
participant, shelf life of each component, percentage of discarded blood bags, 
reasons for discarding). 
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(vi) Infrastructure data (number of BDC sites in the country, capacity per parking lot 
and waiting areas, number of medical examination rooms, number of physical 
assessment rooms, number of recovery rooms and number of rest rooms).   
3.2.2.2.Data retrieved from Hematos IIG, Medinfo System database 
Another quantitative data set was obtained from a retrospective analysis carried out at 
HMC-BDC data during the 2013-2018 period using the Hematos IIG, Medinfo System 
database. Authorized staff belonging to the Laboratory Information Technologist (LIS) 
team of DLMP provided us with the raw data. This data was in turn classified into: 
(i) Number of volunteer donors in HMC-BDC versus the number of volunteer donors 
in campaigns per month and year. 
(ii) Number of units collected per year. 
(iii) Nationality of the donors. 
(iv) Gender of the donors per year. 
(v) Percentage of services provided by the HMC-BDC per year (platelet apheresis, 
Therapeutic plasma exchange and RBC exchange). 
(vi) Percentage of deferral due to self-deferral, medical interview and physical 
examination 
(vii) Percentage of blood wastage.  
These raw were further analyzed to assess the current and future blood donation demands.  
 
3.3. Forecast Model 
Since our collected data falls under the category of “Time series”, we choose to 
implement the Autoregressive Integrated Moving Average (ARIMA), widely known as 
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Box-Jenkins (BJ) method to develop a forecast model. This automatic BJ procedure is 
mathematically structured as being a useful tool for analyzing probabilistic or stochastic 
characteristics of single time series. In order to project blood donors demand in the coming 
four years, two datasets were required; (i) total number of volunteer donors per month and 
year (dependent variables) and (ii) number of populations per year (independent variables). 
The donor’s data was retrieved from January 2013 to December 2018 from the Hematos 
IIG, Medinfo System database, whereas population number were collected from Ministry 
of Development Planning and Statistics’ official web site.  
The historical data of donors and the corresponding annual population were plotted in the 
STATA software to check for an increase or a decrease in the blood demand over the 
observed period. In order to implement the time series ARIMA forecasting model, 
statistical stationarity between variables (mean, variance, autocorrelation, etc) over a 
period is should be achieved. As such we assumed statistical stationarity and we tested 
our assumption using Dickey Fuller test. The result revealed a p-value <0.05, indicating 
statistical stationarity (Table 1) Also, stationarity was further confirmed by a lag value 
ranging between (0 and 9) for one stretch of the data sets. Accordingly, stationarity was 
further confirmed.  
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Table 1: Dickey Fuller Test Results 
 
 
 
To fit the donor’s data into the model, the ARIMA features (AR): “variables regressed on 
own lagged or prior values”, (MA):“past error multiplied by a coefficient” and (I): “data 
values have been replaced with the difference between their values and the previous values 
(and this differencing process may have been performed more than once)” were then 
calculated using Bartlett’s formula. In brief, The Moving Averages (MA) value was 
calculated using Correlogram/Autocorrelation function plot (ACF plot) with a calculated 
autocorrelation and correlation ranging from -0.01 to 0.4 (Figure 1). Partial autocorrelation 
in the selected time series was extracted, Partial Correlogram/ pacf plot was used, and 
partial autocorrelation was detected (Figure 2). The AR(p) value of ARIMA model was 
further calculated in a similar way. From the aforementioned interpretations, I was 
concluded to be 0; therefore, the fitted model used for forecasting was ARIMA (1,0,1) for 
count and population (Table2). 
                                                                              
       _cons     807.9413   122.1414     6.61   0.000     564.2119    1051.671
      _trend    -1.443054   .5832641    -2.47   0.016    -2.606939   -.2791688
         L1.    -.8273585    .120118    -6.89   0.000     -1.06705   -.5876668
        prop  
                                                                              
D.prop              Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
MacKinnon approximate p-value for Z(t) = 0.0000
                                                                              
 Z(t)             -6.888            -4.104            -3.479            -3.167
                                                                              
               Statistic           Value             Value             Value
                  Test         1% Critical       5% Critical      10% Critical
                                          Interpolated Dickey-Fuller          
Dickey-Fuller test for unit root                   Number of obs   =        71
. dfuller prop, trend regress
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Figure 1: ACF plot for ARIMA in STATA. 
 
 
 
Figure 2: Partial Correlogram for ARIMA in STATA 
 
Auto-correlated lags 
Acceptance Region 
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Table 2: ARIMA Model (1,0,1). 
 
 
 
3. Statistical analysis 
Data analysis was done using Excel 2016 and categorical data were presented as 
percentages. The time series analysis and graphs of forecasting (ARIMA) model were 
created in STATA/SE version 15. Differences between compared groups were considered 
statistically significant, when the calculated P-value was ≤ 0.05. 
  
      confidence interval is truncated at zero.
Note: The test of the variance against zero is one sided, and the two-sided
                                                                              
      /sigma     210.5899   19.72885    10.67   0.000      171.922    249.2577
                                                                              
         L1.     .8474895   .2183135     3.88   0.000      .419603    1.275376
          ma  
              
         L1.    -.6899838   .3113068    -2.22   0.027    -1.300134   -.0798337
          ar  
ARMA          
                                                                              
       _cons     1016.579   262.4644     3.87   0.000     502.1584        1531
         pop     499.9582   103.0571     4.85   0.000       297.97    701.9465
count         
                                                                              
       count        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                               OPG
                                                                              
Log likelihood = -487.4361                      Prob > chi2       =     0.0000
                                                Wald chi2(3)      =      60.70
Sample:  2013m1 - 2018m12                       Number of obs     =         72
ARIMA regression
Iteration 7:   log likelihood = -487.43608  
Iteration 6:   log likelihood = -487.43608  
Iteration 5:   log likelihood = -487.43614  
(switching optimization to BFGS)
Iteration 4:   log likelihood = -487.43673  
Iteration 3:   log likelihood = -487.44238  
Iteration 2:   log likelihood = -487.45007  
Iteration 1:   log likelihood = -487.81067  
Iteration 0:   log likelihood =  -488.4719  
(setting optimization to BHHH)
. arima count pop, arima(1,0,1)
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CHAPTER 4: RESULTS 
4.1.Current standing of the HMC-BDC and its infrastructure 
The available assets, personnel and campaign logistics of the BDC were evaluated 
and are summarized in tables (3,4 and 5). 
4.1.1 Available assets 
 
Table 3: Available Assets at the HMC-BDC 
Infrastructure Capacity Logistics 
Registration area 1 area 
4 donors at the 
same time 
Chairs in male 
waiting area 
27 chairs 
Waiting area 
1 area for males 
1 area for 
females 
27 male donors 
11 female donors 
Chairs in female  
waiting area 
11 chairs 
Medical 
interview room 
1 room shared by 
males & females 
1 donor only 
Beds in phlebotomy 
room 
6 beds in male 
section 
2 beds in female 
section 
Physical 
examination 
room 
1 room shared 
between male & 
female 
1 donor only T-rack 
25 (6 in male 
section, 2 in 
female section, 6 
for folded beds, 
11 for mobile 
cars) 
Phlebotomy 
room 
1 room for males 
1 room for 
females 
6 male donors 
2 female donors 
 
Trima machine  
4 (3 in the BDC 
and 1 backup) 
Recovery room 
1 room for males 
No room for 
females 
12 donors 
Optima machine 
 
8 (2 available in 
National Center 
for Cancer Care 
& Research 
(NCCCR) and 4 
available in 
Hamad hospital) 
 
Restroom 
1 WC for males 
1 WC for 
females 
2 males 
1 female 
Campaign cars 3 
Parking lot 1 area 8 cars Folded beds 6 
 
  
   
30 
 
4.1.2 Personnel  
The working days of the HMC-BDC are from Saturday to Thursday. During those 
days, the Center opens for 16 working hours, with two shifts (7:00 am-3:00 pm) and (3:00 
pm -10:00 pm). All staff members working at the BDC are assigned different 
responsibilities. In general, staff in specific locations vary according to the needs and 
availability of personnel table (3 and 4).  
 
 
Table 4: Staff Number and Duty Schedule at the HMC-BDC 
Drivers Clerks Nurses 
3 
8 
5 (clerks are assigned in BDC) 
3 (clerks are assigned for 
campaigns and other 
responsibilities) 
 
25  
 
schedule (1 shift) 
Morning shift: 3 clerks 
Afternoon shift: 2 clerks 
Weekend: 1 or 2 clerks 
(overtime) 
 
Morning shift/ Afternoon shift: 
1 nurse conducts Medical 
interview 
1 nurse performs Physical 
assessment 
5-6 responsible for blood 
collection 
Rest of nurses are assigned for 
other duties outside the Center; 
either in campaigns or taking 
care of patients in Hamad 
hospital sites and NCCCR 
 
 
4.1.3 Mobile services provided by the HMC-BDC 
In addition to the fixed services provided by the HMC-BDC, the Center is equipped 
to provide mobile service in various areas in the country; mainly through mobile cars. The 
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Center has two car models with difference in their capacities and the number of beds that 
they could accommodate. Usually folded beds, which are easier to carry when campaigns 
are held into tall building and towers are used. The number of nurses vary according to the 
size of the campaign (Table 5). In general, off-site one shift (8 hours) campaigns can 
increase the stock numbers by 96 units, while two campaigns per day will enrich the stock 
by 192 units. 
 
 
Table 5: Mobile Services Provided by the HMC-BDC 
Number of 
mobile cars 
Number of 
nurses/car 
Number of 
campaign/day 
Number of 
beds/car 
Number of 
clerks 
Folded 
chair 
3 
Flexible 
according to 
the size of the 
campaign 
4-5 nurses 
(2-3 nurses to 
withdraw blood 
for donor, 1 
nurse for 
medical 
interviewing, 1 
nurse for 
physical 
assessment) 
Average of one 
campaign/ day 
1 car contains 6 
beds 
2 cars contain 4 
beds 
1/car 6 beds 
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Figure 3: The ongoing blood supply chain processes in the HMC-BDC and its corresponding units.  
Indicates the different sites as the BDC, the Component Processing Units and the Donor Marker Testing 
Units, while  indicates major processes in each unit,  demonstrates the actions taken (deferring donors or 
rejecting sample), and  indicates the blood screening results.  
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4.2.Blood collection process  
The blood donation process encloses four main steps, each of which follows specific 
guidelines (Figure 4). 
 
Figure 4: Summarizes the allocated time for each step of the blood donation process.  Represents the 
main steps prior to blood collection with their allocated times  Represents the time needed for collecting 
whole blood or for platelet/ plasma apheresis. 
 
 
4.2.1 Donor reception and registration 
The blood donation process at HMC-BDC, and like all other international set 
processes, starts by obtaining the needed information from the donor during the registration 
phase for identification purposes. In the BDC, registration is done through the “Medinfo 
Hematos_IIG” system. Regular donors are usually asked to present their donor’s 
identification cards or any other identification form (Qatar Identification card (QID), Qatar 
driving licenses, Health card), while new donors are asked to show their QID, Qatar driving 
license or Health Card. During registration, regular donors are checked for any previous 
deferrals or abnormal screening tests result. If there is no deferral record, donor will be sent 
for medical interview. Figure (5) illustrates the allocated time for registration and evaluates 
the accommodation capacity of donors on daily basis. 
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4.2.2 Medical interview 
During the medical interview, donors will be asked about their health, medication 
history and past travels using a Blood Donor History Questionnaires (DHQ) that encloses 
50 to 60 questions. The questionnaire template used at the HMC-BDC and the types of 
questions asked are profoundly based on the criteria of the AABB with minor 
modifications. Few years ago, Qatar had very strict blood donation criteria; however, 
HMC-BDC reconsidered some of those criteria because of a 62% recorded decrease in the 
number of donors, due to malaria related deferrals. All answers in the questionnaire are 
confidential. The interview room is separated where only the donor and the assigned staff 
are allowed exclusively inside. After the completion of the medical interview, the donor 
signs consent form and proceeds to the physical examination test to check for any 
remarkable signs and symptoms of illness or any conditions that results in blood donation 
deferral.  
A medical interview usually takes between 3-5 minutes depending on the case. We based 
our calculations on the longest time an interview might take (5 minutes) as some donors 
might stay for more than 3 minutes in the interview room especially if addition questions 
are asked. In such a scenario, the medical interview represents a bottle neck where more 
than half of registered donors remain un-interviewed at the end of the day. This problem 
could be simply resolved, and long waiting queues could be therefore avoided by providing 
additional interview rooms (Figure5). 
4.2.3 Physical examination 
The conducted physical examination results are documented in the donor’s file in 
Medinfo, Hematos IIG system. Table (6) summarizes the physical examination criteria 
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needed for donors to become eligible for whole blood and platelets apheresis donation at 
HMC-BDC. 
 
 
Table 6:Physical Examination Acceptance Criteria 
 
Description 
Accepted values Deferral duration 
Minimum Maximum 
Less than 
minimum 
value 
Greater than 
maximum 
value 
W
h
o
le
 b
lo
o
d
 d
o
n
a
ti
o
n
 
Body Weight 
(kg) 
50 - 365 Days 365 Days 
Hemoglobin 
(g/dl) 
13.0 
(Male) 
18 30 Days 90 Days 
 12.5 
(Female) 
Blood 
Pressure 
(mmhg) 
100  
(systolic) 
180 
(systolic) 
15 Days 15 Days 
60 
(diastolic) 
100 
(diastolic) 
Pulse Rate 
(cpm) 
60 100 15 Days 15 Days 
Temperature 
(oC) 
36.1 37.5 7 Days 7 Days 
P
la
te
le
t 
a
p
h
er
es
is
 
Platelet 
Counts     
(x10-3/ul) 
 
150 500 2 Days 2 Days 
 
 
4.2.4 Donor phlebotomy 
After underdoing the physical examination test, eligible donors are sent to the 
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phlebotomy room or collection room to undergo blood collection procedure. In HMC-
BDC, about 450 ml of whole blood is collected. If blood withdrawn takes places between 
7:00 am to 11:00 am, then blood will be collected in Cryo bag. If blood withdrawal taken 
places after 11:00 am, then blood will be collected in Reveos three components blood bag 
sets. During the collection process, the blood bags are placed on racks for gently mixing of 
blood with the additive solution, improving the consistency of whole blood and avoiding 
clotting. The HMC-BDC follow specific guidelines to ensure that the acceptable criteria 
for whole blood collection are met: (1) the collection time of any blood unit should not 
exceed 15 minutes and (2) the acceptable volume/weight of whole blood unit should be 
405 ml-495 ml (427 grams- 521 grams). 
The volume of blood collected from donors is usually based on several factors including 
the proportionate amount of anti-coagulant to blood volume in the blood bag and to the 
weight of the donor. Generally, short drawn or over drawn units are not suitable for 
transfusion because the volume in the container may not be proportionate with the amount 
of anticoagulant in the blood bag. Usually, the whole blood collection process should not 
exceed 15 min. The variation of time from one donor to another depends on the size of 
donor’s vein. The problem lies however in the fact that not all available 6 beds in the male 
section are always used for whole blood donation; because they happen to be used 
sometimes for other purposes as well like therapeutic or platelets apharesis. Therefore, only 
3 beds are usually used for whole blood collection in the male section. Accordingly, we 
calculated the capability of accommodating whole blood donors based on 5 beds (3 beds 
in male and 2 beds in female section) (Figure 5).  
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Figure 5: Process of blood collection and donor capacity on daily basis.  Indicates the main stages prior 
to the blood collection process with allocated time for each stage.  Demonstrates the number of donors 
that can be registered, medically interviewed, physically examined and processed for blood collection 
during the first hour and per working day.  Indicates the bottle neck step which need to be resolved to 
avoid losing donors. 
 
 
 
4.3.Blood processing and screening 
After blood withdrawal, collected blood samples are sent to the Donor Marker 
Testing Unit, for infectious markers testing. The rest of the blood samples and their 
corresponding blood bag are delivered to the Component Processing Units for 
immunohematological testing and blood separation into major blood components. Both the 
Donor Marker Testing Unit and the Component Processing Units are located on the upper 
floor of the BDC. Whole Blood released in Cryo bags should cool down and get transported 
at 1 to 10⁰C temperature to the Blood Component Processing Units. On the other hand, 
whole blood collected in Reveos bags and apheresis platelets should be transported at 20-
24⁰C. Throughout our site visits to the Center and its corresponding units, we have noticed 
that both units are fully equipped with highest standard instrumentation and up to date 
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reagents and material are used to detect pathogens, and therefore reduce risk of disease 
transmission. 
4.3.1. Component Processing Unit 
The Component Processing Unit operate from Saturday to Thursday between 6:00 
am to 5:00 pm. This unit contains only 5 technical staff that are distributed over three shifts. 
The first shift starts at 6:00 am and ends at 2:00 pm, the second starts at 7:00 am and ends 
at 3:00 pm, and the third shift starts at 9:00 am and ends at 5:00 pm. In this unit, the 
laboratory instruments are backed-up by havening two instruments of the same kind to 
ensures non-stop laboratory operations and guarantee continuous service in case of 
equipment breakdown. Table (7) provides a list of the available equipment at the 
Component Processing Unit. It is worth mentioning here that this richness in equipment is 
limited by the available space, which restricts the ability of the staff to work freely.  
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Table 7: Available Equipment at the Component Processing Unit 
Equipment Quantity available Equipment Quantity available 
Serology centrifuge 2 Weight scale 2 
Reveos centrifuge 4 Tube sealer 2 
Cryo refrigerated 
centrifuge 
2 
Cryoprecipitate bath      
(1-6oC) 
2 
Plasma extractor 8 Mirsol system 3 
Ortho Innova 
analyzer 
2 Holder 4 
Refrigerator            
(1-6oC) 
5 
(2 fridges shared with 
Blood Marker Testing 
Unit) 
Freezer maintained at         
-18 oC or lower 
 
4 
(4 freezers shared 
with Blood Marker 
Testing Unit) 
Platelet 
incubator/agitator 
(20-24oC) 
2 
 
 
In the receiving area of the Component Processing Unit, blood bags are checked once 
received for (i) integrity of the bag and its open sealing (ii) integrity of the label (iii) volume 
collected (450 ±10%) (iv) visual screen (lipimic, icteric, hemolysis, clot, unusual color of 
blood) and (v) lot number and expiration of blood bag used.  
4.3.2. Immunohematological testing and process of blood components production 
After the aforementioned steps, the staff proceed to perform Immunohematological testing 
and blood component preparation in parallel. Immunohematological testing include: (i) 
determination of ABO group and Rh types for all collections (ii) detection of unexpected 
antibodies to red cell antigens for donors and (iii) routine (non-mandatory) testing for Rh 
and Kell phenotyping for all donors. Many of the procedures performed at the component 
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processing unit including filtration, plasma extraction, platelets pooling, Riboflavin (B12) 
addition, FFP thawing for Cryoprecipitated AHF preparation and IQC assessment are 
performed manually. Therefore, this process requires a lot of effort and is considered time 
consuming. From our observations, we concluded that around 70 blood bags are prepared 
on average, every 8 working hours. In brief, the first staff is responsible for receiving 
samples and for performing the manual ABD confirmation test, the second staff is assigned 
for ABO/ Rh CED typing, antibody screening and Rh/Kell phenotyping using Ortho Innova 
analyzer, the third staff is responsible for pooling platelets and plasma preparation, and the 
fourth staff is in charge of Cryo and Reveos blood bag separation. Apart from these 
observations, we were not able to determine the exact time allocated for these tasks because 
of several factor related to quantity and types of blood bags, receiving time, other duties 
which are handled by laboratory staff such as inventory checking, in addition to the 
differences in the skills of the staff performing these jobs. 
Different blood components can be obtained from one unit of 450 ml of whole blood and 
can be used later for different medical purposes. In general, blood collected in Cryo bags 
should be processing on the same day (2-8 hours post collection), in order to obtain PRBCs 
and FFP, for further production of Cryporeciptated AHF. On the other hand, blood 
collected in Reveos blood can be left for the second day or processed 2 hours post collection 
to produce PRBCs, platelets, plasma and Residual of leukocyte (buffy coat). We have noted 
significant dissimilarities in the handling, preparing, and storage of whole blood according 
to the type of bag used and the need components (Table 8).  
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Table 8: Differences Between Reveos and Cryo Blood Bags. 
Action Reveos bags Cryo bags 
Storage environment post 
collection 
18-28oC 
(room temperature) 
1-6oC 
Shelf life post collection 
24 hours 
(overnight) 
2-8 hours 
Whole blood units processing in 
the machine 
A minimum of 2 to 24 hours 
(including filtration time) 
A minimum of 2 to 8 hours 
(including centrifugation time) 
Centrifuge 
Reveos automated blood 
processing system 
Cryo refrigerated centrifuge 
Capacity of blood bags 4 sets of bags 6 sets of bags 
Centrifugation period  30 min 10 min 
Extraction of blood components Automated  Manual 
 
 
After plasma separation from both bags, it gets treated with Mirsol to inactivate the 
pathogens. The interim platelet unit is generally ready at this stage for further processing, 
(resting with agitating, pooling with 4-6 other interim platelet units and filtration with a 
Platelet Pooling Set) to create a final pooled platelet. All platelet from a female donor are 
discarded before the pooling process to avoid any complication post transfusion like 
Transfusion-Related Acute Lung Injury (TRALI), due to antibodies in blood of pregnant 
women [90]. Agitation is essential to prevent platelet clotting. Pooled platelets are also 
treated with Riboflavin and Mirsol PRT. When pooled platelets leukocytes reduced are 
prepared, the pH and leukocytes count is usually taken into consideration. Apharesis 
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Platelets are in turn treated with Riboflavin and Mirsol PRT. 
 Residual of leukocyte (buffy coat), which contain a large number of leukocytes with few 
erythrocytes and granulocytes get discarded in specific waste container. Sometimes, the 
Component Processing laboratory provides leukocyte bags (source of PRBCs) for other 
laboratories to be used in research or for quality control purposes. 
4.4. Donor marker testing unit 
The Donor Marker Testing Unit operates from Saturday to Thursday between 6:00 
am and 2:00 pm and have four technical working staff. In the receiving area of the Donor 
Marker Testing Unit, blood samples are checked for labelling, integrity, hemolysis and 
volume. Once checking is completed, blood samples will be centrifuged before applying 
the screening test of interest. The unit contains a number of different instruments that are 
found in duplicates (Table 9). 
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Table 9: Assessing the Availability of Equipment at the Donor Marker Testing Unit 
Equipment 
Quantity 
available 
Capacity 
Serology centrifuge 2 - 
Dynex DS2® 2-Plate ELISA processing 
system 
2  (100 samples/run) requires 5 hours 
ARCHITECT machine 2 
Maximum capacity 65 samples/batch 
(Batch systems) 
Auto-LIA- 48 processing system 2 48 sample require 4-5 hours 
Procleix systems  2 
100 samples require 5 hours          
(Batch systems) 
Refrigerator (1-6oC) 
5 (two of them are shared with the Component 
Processing Units) 
Freezer maintained at -18 oC or lower 4 (shared with the Component Processing Units) 
 
 
4.4.1 Blood screening and Pathogen inactivation 
The Donor Marker Testing Unit performs a number of tests to assure the safety of 
blood delivered to patients. This unit has updated facilities and instruments, some of which 
are considered cutting-edge instruments in terms of technology and price. The different 
tests performed in the unit include: Malaria tests, Human immunodeficiency virus (HIV) 
antibody test, Treponema pallidum (Syphilis) antibody tests, Hepatitis tests (HBsAg, anti-
HBc and HCV antibody), Human T cell leukemia virus (HTLV) antibody tests and Nucleic 
Acid Testing (NAT). 
Dynex DS2® 2-Plate ELISA processing system, is only used for malaria antibodies 
detection in blood sample of donors coming from endemic region. Malaria Ag test (rapid 
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test) is carried out to identify the type of Plasmodium species (Plasmodium falciparum, 
P.vivax, P.ovale and P. malariae). If the results of samples are positive for malaria Ab and 
malaria Ag, the unit should be discarded. Also, HIV Ag/Ab assays, Syphilis antibody 
detection, HTLV antibody detection, HBsAg, HBcAb and anti-HCV detection are 
performed in the unit using the ARCHITECT machine which is based on the 
Chemiluminescent Microparticle Immunoassay principle. Any positive result of these tests 
will be followed by INNO-LIA tests on Auto-LIA- 48 Processing System for further 
confirmation.  
Despite the expensive cost of NAT, which is based on the Transcription-Mediated 
Amplification technique, it is considered a mandatory test for HBV, HCV and HIV 
detection due to its sensitivity and specificity for viral nucleic acids. This reduces the risk 
of missing the identification of virus infection during the window period. NAT is 
performed on Procleix systems. According to NAT results, the blood unit will be either 
dispatched for clinical use or discarded. 
4.5. Blood quarantine 
All unscreened donated blood and its components are placed in the quarantine until 
the screening for infection markers is completed and the suitability of donated blood for 
therapeutic use is determined. Screened and unscreened units are generally stored in 
separate fridges. Reactive or positive blood bags are labelled “Not for transfusion” and 
removed from quarantined stock to separate and secure stores to be discarded or to be used 
for other purposes as quality assurance or research purposes. 
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4.6. Blood storage 
All blood components are stored in controlled temperature and conditions to 
maintain the recommended shelf life (Table 10). 
 
 
Table 10: Blood Components Storage Shelf Life 
Component Storage Shelf life Additive solution 
PRBCs 1-6 0C 42 days SAGM 
FP24 
-180C 1 year - FFP 
Cryoprecipitated AHF 
Pooled platelets 
leukocytes reduced 20-240C 7 days PAS 
Apheresis platelets 
 
 
During the storage period, IQC is implemented to check the quality of blood components 
and therefore guarantee using effective, safe products with lowest risks. 
4.7. Blood distribution to hospitals and health care institutions 
In HMC, the dispatching of blood components starts from the Component 
Processing Unit to the blood bank laboratories and finally to other facilities and medical 
centers to meet their transfusion requirements and complete their inventory unites. The 
HMC Receiving Facilities includes Hamad General Hospitals (HGH), Heart Hospital 
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(HH), Al Wakra Hospital (AW), Al Khor Hospital, Dukhan/Cuban Hospitl (DH), Qatar 
Rehabilitation Institute (QRI) and other private hospitals. 
Proper shipping containers are used to maintain a proper transport temperature that is 
appropriate for the components. For instance: RBCs and Plasma Frozen products including 
PF24, FFP, Cryoprecipitated AHF, and Plasma Cryoprecipitated Reduced are transported 
at a temperature of ranging from 1 to 10 0C, while platelets must be transported at 
temperature between 20 to 24 0C. Moreover, blood and blood components are transported 
using double insulated, proof security sealed containers to ensure that optimal temperature 
ranges are maintained during transportation. 
4.8.Blood disposal 
Blood and blood products are generally discarded if they do not meet certain 
specified criteria. Scenarios that usually result in discarding blood and blood components 
include (1) units that are positive for infectious markers (2) unsuitable products such as 
under/over weight blood bag or those that have not been maintained at proper temperatures 
(3) outdated units (4) leaks detected in the units (5) blood component that do not meet the 
inspection criteria (6) failure of the blood unit to meet the set quality standards after IQC 
assessment or (7) insufficient storage space. Unfortunately, a high percentage of collected 
blood units is ending being discarded either in the pre-analytical or post analytical phase 
of the blood supply chain process. In the pre-analytical phase, 5-10% blood is discarded 
due to various technical issues, while this percentage is slightly higher in the post-analytical 
phase (more than 20%) due to the screening test results. 
Due to confidentiality considerations, we were unable to assess blood wastage in the BDC. 
We were also unable to assess the number of current available stock for each component 
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and blood group, the number of requested units and blood transfusion units. Also, 
information obtained about departmental and blood requests, needs and misuses were not 
provided. The only piece of information we obtained from the Head of Transfusion 
Medicine of Blood Banks in that regard was that there is a high percentage of blood and 
blood product wastes due to improper clinical practices. The Emergency Department 
usually consumes blood units the most because of urgent blood transfusion for life saving 
and for compensating for the sever blood loss as in case of accidents, accidents or blood 
vessel rupture. Many clinicians in the Emergency Department prefer to order O positive 
blood type for urgent and non-urgent cases to avoid the possibility of any complications 
that may affect the patient’s life. This practice leads to shortage in O positive blood stock 
and generally affects the scheduled operations resulting in delays. Interestingly, historical 
data shows that 39% of blood wastage is mainly due to the expiration of the units, storage 
insufficiency and unaccepted temperature.  
4.9. Descriptive analysis  
In Qatar, blood service practices are based on voluntary unpaid donations. The 
BDC at HMC is the only available center that offers blood services across the country. 
Over the past six years, more than 180,000 people from over 100 different nationalities 
have been registered as donors. On average, 13% (21231) of those registered donors are 
Qataris, while the remaining 87% (140554) are non-Qataris. Figure (6) represents the 
distribution of Qatari vs non-Qatari donors over a six period (2013-2018). 
Among different non-Qatar nations, Indians donate blood mostly especially the 
Lutheranisms. The Lutheran Church: encouraged its members to donate blood because it 
is “an expression of sacrificial love for a neighbor in need” [91]. Usually, the ethnic groups 
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cluster and arrange with the administrator personnel at the BDC to donate blood during the 
weekends. Likewise, Indian Sikh Nation (Sikh Quom) group together and organize 
campaigns to donate blood as attribute to the events of 1984, where civilians Sikh were 
targeted by aggression and attack. The Philippinoes also participate in blood donation 
during certain religious occasions. Some blood donation campaigns take place in the BDC 
on Fridays.  
 
 
 
Figure 6: Percentage of registered Qatari versus Non-Qatari donors. The figure shows the distribution of 
blood donation based on nationality in the HMC-BDC over a six years period ranging from 2013 to 2018.  
Represents Qatari donors and  represents non-Qatari donors 
 
 
In case of emergency or low blood stock (shortage in specific blood group or 
platelets), HMC-BDC sends announcement in different languages broadcasts via radios, 
on Qatar TV channels, by short messages (SMS), through twitter or through any other mean 
of social media. From a statistical stand point, the number of male donor’s dominant female 
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ones. The average percentage of male donors for the past six years was (97%; 36687) as 
compared to (3% ;1088) female donors (Figures 7). This could be due to several reasons 
including low hemoglobin levels and pregnancy conditions, or lack of privacy in the 
Center. 
 
 
  
Figure 7: Percentage of male donors versus female donors registered in the HMC-BDC over a six years 
period ranging from 2013 to 2018. (a-b)  Represents the average percentage of male donors and  
represents the average percentage of female donors 
 
 
The graph shows an average increase of whole blood donation over the past six years by 
5%. For instance, a continuous upward trending (8.4%) between 2017 and 2018 reaching 
(30209) donors (Figure 8). 
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Figure 8: Donors demand pattern over a six years period ranging from 2013 to 2018.  Represents an 
increase in the whole blood donation demand except in 2017.  Represents total number of donors. 
 
 
In each step of the blood donation process, a number of registered donors ends-up being 
deferred due to eligibility standards. The highest average percentage of donor deferral for 
the past five years was at the medical interview stage (26%; 10492) compared to physical 
assessment deferral (9%;27480) or self-deferral after registration (5%;2195). Interestingly, 
62% of the 26% deferred at the medical interview stage were deferred due to malaria 
criteria (Figure 9). 
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Figure 9: Percentage of deferred donors versus eligible donors in blood donation process.  Indicates the 
eligible donors (60%)  indicates defferal due to physical assessment  indicates defferal due to medical 
interview (26%) and  indicates defferal due to the registration step (5%).  indicates defferal due to malaria 
criteria. 
 
 
Usually, these donors either visit the BDC at HMC campus or participate through off-site 
campaigns organized by the state. The percentage of blood collected in the BDC was 
relatively higher than blood collected through campaigns. Over the past six years, the 
number of donors has slightly increased reaching 30209 donors in 2018; 13697 of which 
participated in off-site campaigns and 16512 visited the center in 2018 (Figure 10).  
 
  
 
Deferrals During Blood Donation Process 2014-2018 
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Figure 10: Percentage of part taking donors donating either at HMC-BDC or through off-sight campaigns 
over a six years period ranging from 2013 to 2018.  Denotes the percentage of donors participating 
through-off-sight campaigns and  denotes the percentage of donors donating at BDC. 
 
 
Different ministries, governmental institutions, petrol companies, embassies and schools 
participate in a series of blood donation events in shopping centers and other prominent 
places in Qatar. Annual campaigns schedule begins with the Ministry of Defense and Qatar 
Armed Forces that usually succeed in involving large numbers of participants in these 
campaigns. The Medical Manager at HMC-BDC is usually engaged in arranging such 
needed campaigns along the year. Additionally, the BDC, receives frequent requests from 
schools or companies to provide cars when such activities are organized. These requests 
are generally accepted when the number of volunteers is greater than or equal to thirty.  
Whether through campaigns or visits to the BDC, blood is usually donated for different 
purposes including whole blood or single component (platelet apheresis) usage or for 
therapeutic purpose (Therapeutic phlebotomy, Therapeutic plasma exchange or RBC 
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exchange). On average, from (27933) donors over the past six years, 97% (26964) were 
used for whole blood collected procedures, 2% (690) for platelet apheresis procedures, 
0.8% (297) for Therapeutic plasma exchange and 0.2% (42) for RBC exchange (Figure 
11). 
 
 
 
Figure 11: Percentage of donors participating in different service provided by the HMC-BDC over a six 
years period ranging from 2013 to 2018.  Indicates whole blood collection,  platelet apheresis,  
Therapeutic plasma exchange, and  RBCs exchange. 
 
 
Over the past five years, the average percentage of whole blood disposal of the BDC and 
its corresponding units reached (61%), while blood wastage in other facilities was (39%). 
This percentage can be justified due to technical issues, positive infectious markers testing, 
outdated units and other reasons (Figure 12).  
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Figure 12: Average percentage average of blood disposal in HMC-BDC and other facilities over a five 
years period ranging from 2014 to 2018.  Indicated the blood wastage in the BDC and  indicated the 
blood wastage in other facilities. 
 
 
4.10. Forecasting  
In this study, we predicted the demand of whole blood donation for the four coming 
years using two main variables: the number of blood donors on monthly basis versus the 
population of Qatar. Our established forecast model shows a significant increase (26%) in 
the expected number of donors who will visit HMC-BDC or participate through off-sight 
campaigns in 2022 (Figure 13).  
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Figure 13: Predicted number of blood donors in Qatar from 2013 to 2022. Represents the predicted 
demand of whole blood donation in Qatar for the next four years. Both upper and  lower lines 
indicate confidence intervals for the predicted period. 
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CHAPTER 5: DISCUSSION 
In 2022, Qatar will witness a historical event by hosting the World Cup. According 
to the current statistics, Qatar is expecting around 1.3 million football fans to visit Doha in 
2022. Such a mega event requires proper preparation and readiness in both the 
infrastructure and health care sectors. Previous FIFA World Cup events data illustrates 
unexpected and remarkable increase in demand for health care facilities because of an 
increase in the number of patients during and after each event [92]. Many International 
standards for health and medical services should be met in this event particularly those 
related to health care facilities, emergency medicine provisions, and specific national 
provisions for medical services, including (staffing, infrastructure and anti-doping 
services). 
The readiness of the BDC for accommodating the required number of donors is on top of 
the to-do list. The BDC is of particular importance to all medical practitioners because 
blood serves as a lifesaving element especially when medical complications occur. As 
such, a proper assessment of blood resource availability, stock management, and a 
forecasting model that predicts future needs can guarantee quality service and therefore 
help in overcoming any obstacle that could be faced in this event. In this study, we have 
assessed the current standing of HMC-BDC infrastructure and blood donation related 
activities including blood collection from donors, blood processing, screening, storage and 
distribution of blood components to all hospitals and healthcare institutions. This 
assessment revealed our current standing in term of readiness to host the World Cup event.  
The HMC-BDC is the sole center that provides blood services in the country. Based on our 
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collected data, 55% of volunteered donors were received on the premises of the Hamad 
Medical corporation campus at the BDC and 45% participated through different off-site 
campaigns across the country in 2018 (Figure10). The role of BDC is not limited to blood 
donation, but also provides therapeutic services such as Therapeutic plasma exchange, 
RBC exchange, reductive leukoheresis, reductive thrombapheresis, stem cell collection and 
photopheresis, which are performed in Hamad hospital facility and in the NCCCR. These 
kinds of services are supported by the Transfusion Medicine Department staff and by the 
available equipment. By evaluating the origin of donation purposes from 2013 to 2018, and 
based on our statistical data, the majority of donors (97%; 26964) came for whole blood 
donation compared to (2%; 690) for platelets apheresis (Figure11). 
Collectively, the BDC and its corresponding units such as the Donor Marker Testing Unit 
and the Component Processing Unit are fully equipped with high standard instruments and 
practice blood withdrawal and processing as per the guidelines and regulations of the 
AABB and the CE (Table 6).  
First, A powerful software system “Medinfo Hematos_ IIG” is used to provide high 
security for the sensitive information where no third party other than authorized staff can 
access the database (1). The system is linked to the Ministry of Interior which provides 
information on the donor’s identification in Arabic, thus preventing any conflict as 
language related in accuracy. Second, a very stringent of DHQ is used for the medical 
interview to ensure detailed and straight forward answers to determine the donor’s 
eligibility. This leads to the loss of a big number of donors, especially those with long 
deferral periods. Accordingly, in January 2019 the transfusion medicine physician 
revaluated some medical questions enclosed in DHQ especially those with related to 
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malaria and reduced the deferral period from six months to four months based on the 
Australian system. Third, irrespective of the high cost of materials and equipment used in 
the Center and in branching laboratories, the HMC-BDC is designed to be one of the 
leading centers in the world in providing the safest blood with the longest shelf life and the 
fastest collection and processing procedures (Table 7 and 9). In order to approach the safest 
blood, all samples are initially screened for the following infectious markers prior to being 
released for transfusion (HIV Ag/Ab, HTLV-I/II Ab, Syphilis TP Ab, HBsAg, HBcAb, 
anti-HCV, Malaria Ag/Ab and NAT for HBV, HCV and HIV). In addition, HMC uses 
additional protections methods for platelets and plasma such as the pathogen inactivation 
technology that uses riboflavin (vitamin B2) and the Terumo BCT Mirasol system. Blood 
bags (Reveos and Cryo bags) as well contain (nanofilters) which eliminate leukocytes and 
viruses that contain protein membranes. Furthermore, the quality of the platelets is 
improved through the use of additive solution (PAS) which minimize adverse reactions 
associated with plasma transfusion by reducing the Leukocytes and extend the shelf life 
from 5 days to 7 days. Also, the use of SAGM extend the shelf life of RBCs from 35 days 
to 42 days (Table 10). The Donor Center offers fast service for platelets or plasma donors 
by using Trima machine, which consume around 90 minutes for whole the process of 
collection instead of 3 hours or more. Likewise, using an automated blood processing 
system (Reveos) helps in separating more than 200 bags/8 hours into four main components 
which are PRBCs, plasma, platelets and buffy coat (Table 8). Overall the availability of 
back up instruments insures the continuity of all services and the ability to accommodate 
high workload. It is worth noting here that the availability of instrumentation alone is not 
enough, especially with heavy workloads like in a World Cup scenario or in any other 
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scenarios associated with unexpected increase in demands. Therefore, other factors such 
as the employment availability and storage depots could be a barrier in accommodating the 
required quantities. These obstacles will be discussed in the below action plan section of 
this study.  
By comparing the data of over the past six years (2013-2018), we concluded that the 
average blood donation in Qatar has increased by 5%, and the total number of whole blood 
donors was the highest in 2018 (30209) (Figure 8). As a general trend, blood demands are 
in an increasing pace. Despite this slight increase in the total number of donors, the BDC 
is still facing a major problem in meeting the daily benchmark of some blood types 
specifically O positive. Although the blood type distribution may vary according to ethnic 
groups, O positive is considered one of the most common blood types in most of the 
countries including Qatar whose population is distributed into 11.6% Qatari and 88.4% 
Non-Qatari [93]. On average, the Qatari donors represent 13 percent of the total number of 
donors which is considered a relatively acceptable percentage as compared to the 
percentage of Qatari versus non-Qatari population (Figure 6). Yet, if we dissect this 13% 
in depth, we question this percentage in accordance with the of eligibility of the Qatari 
population to donate blood. The causes behind this reluctance should be seriously 
considered to improve the percentage of donation in the coming years. 
In case of emergency or low blood stock, HMC broadcasts the need of blood donors 
through various media tools. The overall data recorded for the past six years shows, 97% 
(36687) male donors as compared to 3% (1088) female donors (Figure 7). This percentage 
of female donors is considered very low compared to the percentage of females in the 
Qatari population (24.6%; 659036 females in 2018) [94]. This low percentage of female 
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donation can be justified due to several clinical reasons for instance low hemoglobin levels, 
pregnancy especially in young women, in addition to lack of privacy in the Center. A study 
conducted by Bani and Giussani shows that female donors represent only 30% of the Italian 
population, which is opposing to the scenario in many other European countries where 
donor distribution is gender similar. Several published data have indicated that this 
discrepancy in gender could be due to deferrals reasons where women deferrals rates are 
usually higher than men deferral rates. This could be due to low levels of hemoglobin, 
which are the most frequent cause of deferral in women, increased possibility of adverse 
reactions in women due to low body weight as compared to men, or difficulties in venous 
access [95, 96].  
5.1.Challenges 
In this study, we categorized the challenges faced by HMC-BDC to meet the benchmark 
of donation into three parts; challenge related to donors, challenge related to infrastructure 
(logistic/personnel/campaigns) and challenges related to awareness. 
5.1.1. Challenges related to donors 
By comparing the percentage of the eligible donors to ineligible ones, we found 
that 40% of the donors were deferred, with the highest percentage of deferral (26%) 
happening at the medical interview stage. It is worth noting here that around 62% of this 
26% deferral is due to the malaria criteria (Figure 9). The stringent criteria of the 
questionnaire is also another challenge that lead to a significant loss in the number of 
donors. For instance, donors who visited malaria endemic area in the past 6 months got 
deferred for 6 months. Qatar receives many donors from malaria endemic areas especially 
those currently recruited to participate in construction plans for the World Cup event. The 
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percentage deferral for this reason was high and the deferral period was long. In addition 
to loosing donors, sometimes although blood is collected, it ends up being disposed mostly 
in BDC unites or other facilities such as HGH, HH, NH and AW (Figure 12). More than 
20 % of the blood bags were discarded during the post-analytical phase due to positive 
infectious disease markers testing. In general, the percentage of discarded blood may 
increase due to the nationality of donors. High percentages are usually detected with donors 
coming from some South Asian countries, due to high prevalence of syphilis and other 
infectious diseases. A recent study conducted by Silverman et al. showed the proportion of 
syphilis and HIV co-infection is relatively high (accounts for 31.0%) in Nepalian people 
[97]. Likewise, high percentage of discarded blood from Egyptian donors is detected due 
to high prevalence of HCV in their originating countries [98]. From the 88.4% of Non-
Qatari residents, Indians account for 24% of the population, followed by 16% Nepalis, 11% 
Filipinos, 5% Bangladesh, and 5% Sri Lankan [99].  
5.1.2. Challenges related to infrastructure and logistics 
As previously described, the HMC-BDC is very small and can’t accommodate 
more than 180 donors/day, although it is the sole blood donation Center in Qatar. People 
living in North or West parts of Doha find it difficult to come to the Center and donate 
blood regularly. Furthermore, the BDC has limited number of chairs in both males and 
females in the waiting area which affects the ability of the donors to read and understand 
the education procedures slowly and carefully. Currently, the calculated daily benchmark 
is 542 donors for all blood groups, with  227 donors for O positive, owing to the fact that 
O positive blood group is commonly requested in cases of emergency. In our study, we 
have detected that failure to meet this benchmark starts at the medical interview stage 
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where only a maximum of 180 donors can be interviewed per day. This problem occurs 
due to presence of only one room, which also lacks complete privacy. As such, this stage 
is considered a bottle neck, and therefore, requires further planning to rectify the arising 
problem. Another constrain is having only one physical assessment room where only a 
maximum of 180 donors can be physically assessed daily (Figure 5). This also leads to an 
increase in the waiting time for each donor, and results in long queue of donors waiting for 
their turn because the available chairs to sit are not enough. This will eventually delay the 
process of blood donation and negatively impact the health of the donor especially in the 
summer season where many donors stand outside the Center, get exposed to the sun, ending 
up being exhausted, dizzy or start vomiting. This decreases the donation process and results 
in wastage of material used (bags) and waste in the effort and time of the staff. Additionally, 
there is a limited number of beds in the phlebotomy room, and the available beds are used 
for different purposes including whole blood donation, therapeutic procedures or platelet 
apheresis. Usually the whole process of whole blood donation takes around 30 minutes. 
Maximum 15 minutes is required to donate blood, while donating plasma or platelets using 
the apheresis machine takes up to 90 minutes (Figure 4). This means that it is very difficult 
to accommodate 542 donors per day if the capacity of the center can’t even reach half of 
that number. 
Some basic facilities are not even available in the BDC. For example, the Center lacks 
female recovery area, adequate rest rooms and a praying room. The Center also lacks 
enough parking lot; a space that can only accommodate 8 cars is available. Donors are 
sometimes subjected to fines due to parking their cars in unauthorized locations or in 
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prohibited parking areas close to the Center. This requires the Medical Manager of the 
BDC to contact the traffic department to waive these violations or to coordinate with the 
traffic department ahead of time to avoid receive these violations. This problem always 
occurs during working days, weekends and on formal holidays. The overall conditions of 
the BDC as not appealing and are discouraging for many people that have an inner will to 
participate. 
In addition to the space constrain, inadequate number of personnel working at the HMC-
BDC is another reason for not meeting the daily benchmark (Table 4). Nurses are 
responsible for various tasks such as medical interview, physical assessment and patient 
phlebotomy. Also, nurses are scheduled during the weekdays to cover the therapeutic 
procedures in HGH or in NCCCR, as well as handling other campaigns duties. Such a staff 
schedule impacts the number of organized campaigns per day. In addition, four laboratory 
staff in the Donor Marker Testing Unit and five technical staff in Component Processing 
Unit cannot handle all the work, which requires a lot of efforts. Therefore, the shortage in 
staff is eventually affecting the overall workflow. Mobile services are another factor behind 
not meeting the daily benchmark. Off-site campaigns are scheduled once every day and in 
very rare events two campaigns per day take place (Table 5).  
Moreover, insufficient storage area in the Donor Marker Testing Unit and in the 
Component Processing Unit is a serious obstacle that is obstructing storage of blood 
products for long time, leading to wastage. 
5.1.3. Challenges related to awareness 
Lack of awareness and motivation programs among different age groups to 
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encourage more people to participate in humanitarian action, explains the low number of 
donors relative to the population size.  
Another problem related to awareness is wastage of blood due to misuse from improper 
clinical practices especially for O positive blood type. Such misuse of blood usually occurs 
because physician lack proper awareness of what to order and how blood or blood 
components should be ordered. The Emergency Department is considered the most 
consuming of blood units. There are many causes of blood loss that require urgent blood 
transfusion like blood needs for life saving purposes after accidents, or blood vessel 
rupture. In HGH-Emergency Department many clinicians prefer to order O positive for 
urgent and non-urgent cases to avoid possible blood transfusion complications. This 
practice negatively affects the blood stock leading to shortage in O positive stock, and 
therefore delays all scheduled operations. 
Predicting the number of donors in the next 4 years is one aspect of a needed 
rectification plan for a better percentage of blood donation over the coming years. Our 
short-term prediction forecasting model showed a significant projection of number of 
donors. In 2022, Qatar's population will increase by 52% reaching 4.1 million people. This 
increase in the population number is positively correlated with a 26% increase in the 
expected number of blood donors during that period. This assumption drew our attention 
to the challenges and obstacles that the HMC-BDC will seriously face in accommodating 
more donors to enrich the blood stock in the coming few years. Therefore, proactive 
strategies by decision makers are needed to prevent blood shortage in the coming years, 
improve donor retention, and reduce the loss in the number of blood donors that could 
occur as a consequence of availability of poor infrastructure. 
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CHAPTER 6: CONCLUSIONS 
6.1. Summary of major findings 
Despite of the advantage of an expected 26% increase in the number of donors 
between 2019 and 2022, the HMC-BDC will not be unable to accommodate this increase 
in the number of donors with the current available facilities and infrastructure. The findings 
of this study show that, although the center and its corresponding units are fully equipped 
with high standard equipment and follow an international guidelines and regulations that 
provide safe blood transfusion, a lot of challenges and obstacles related to donors, 
infrastructure (logistics, personnel, mobile services), and awareness still occur. Here, we 
provide an action plan to able to meet the increasing blood needs in the coming future. 
Accordingly, we suggest to review the strict donor deferral criteria that leads to the loss of 
high percentage of donors, provide alternative solutions to meet the required benchmark, 
develop a better infrastructure that reflect the financial shading of Qatar, and put more 
efforts towards increasing awareness on the importance of participation in humanitarian 
action. 
6.2. Research limitations 
Several limitations have been encountered while conducting this study. First, the 
high confidentiality and restrictions in exploring the healthcare preparation plan for the 
2022 World Cup event was one of the major limitations we faced. Furthermore, the 
confidentiality of blood bank data, which are related to the current standing of blood stock 
and stock management in term of departmental and blood requests, needs and misuse was 
another limitation. In this study we were unable to uncover the exact facilities that misuse 
blood and blood component disposal in all blood supply chains. Moreover, the difficulty 
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in validating the qualitative questionnaire mainly due to lack of literatures related to the 
preparation plan, further complicated some reads in this study. Finally, the major limitation 
was in approaching expert Biotechnicians that could make use of the raw data in 
implementing a time series-forecasting model with sophisticated information such as 
forecasting the daily benchmark for targeted blood group such as O positive. 
 
6.3. Recommendations 
By stitching all the pieces of our study together, the infrastructure at HMC-BDC 
cannot accommodate the large number of donors expected in 2022. Surprisingly, the HMC-
BDC does not actually represent the financial shading of Qatar and its economical 
classification as a super-rich country. As such, certain changes at the level of practices and 
infrastructure should be implemented. To be able to approach the current benchmark, we 
recommend increasing the off-sight campaigns to at least two campaigns per day. During 
the 2022 World Cup event, three off-sight campaign will be even better. From a practical 
perspective, attracting a large number of donors for enough blood supply before the World 
Cup events can be achieved by purchasing new mobile blood collection vehicles that can 
reach people easily in different locations. These vehicles will not be a waste of money 
because they can stand as a backup car when any damage or maintenance problem arise to 
avoid any stop in BDC services that could affect the blood bank daily inventory. Some 
companies provide a customization option to design the vehicle according to specific need 
as installing critical amenities like collection equipment, donor beds, private history rooms, 
canteen areas and short-term storage solutions.  
Many BDCs worldwide have only one centralized blood bank and multiple donor sites 
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(hybrid model) have been shown helpful in collecting more donors. Also, other countries 
have multiple donor sites accompanied with processing units in different area of the 
country where the donation blood will be eventually transported to the main Center. In 
Qatar, we recommended to adapt similar systems. We also, encourage to build a small 
Donor Center close to hospitals outside Doha, such as in Cuban hospital-Dukhan, Alkhor 
hospital that can be easily reached by the people living in the North part of Qatar and by 
employees working in Ras Lafan, Hazm Mebaireek hospital which is located in the heart 
of the industrial Area and Al Wakra Hospital. Although this idea may require a huge budget 
and might take lots of time to get established, it is considered very practical and safe, 
especially in case of disaster. 
Besides that, we also recommend constructing a new donation center or renovating the 
currently available one. The HMC-BDC should reflect the country’s financial standards 
and should provide comfortable conditions for donors. This encourages donors to 
participate more frequently in blood donation and attracts the recruitment of newcomers to 
the Center. The Center should also provide a good working environment for the staff. It 
should contain a wide parking lot, more than 4 clerks, more than 4 interview rooms, more 
than 4 physical assessment rooms, special room for platelet and plasma apheresis for both 
males and females, a special phlebotomy room with at least 10 beds, a prayer room for 
males and females and a spacious waiting area for males and for females considering the 
privacy of females. Also, the Center should be supported with free Wi Fi access and all 
other comfort conditions. Any expansion or increase in the facility of BDC should be 
similarly considered for the Donor Marker Testing Unit and the Component Processing 
Unit to be able to handle this anticipated increase. The Center should also look forward to 
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recruit additional staff (nurses and technical staff). This allows task organization among 
shifts and permits handling heavy workloads comfortably.  
We also, recommended that the BDC changes the regular practice of accepting donors. It 
is highly advisable to collaborate with the Ministry of the Interior in order to obtain the 
necessary information about the blood types of citizens and residents. This type of 
information helps in conducting comprehensive studies to solve problems related to waste 
of time, money and efforts. Accordingly, donors can be contacted, thus guarantying the 
availability of needed donors. This, collaboration with the Ministry of the Interior is 
particularly useful when targeting certain blood type in cases of emergency.  
However, the BDC should not accept a particular blood group if they don’t need it. Donors 
can be contacted later when there is a real need for a specific blood group, especially if 
storage space insufficient. Therefore, implementing mobile application will notify donors 
when blood is needed. The application can be supported with many features such as the 
next donation date, date after deferral, eligibility and donation criteria, working hours of 
the Center, and the location through Google map. Such an application can save a lot of 
money instead of sending SMS. SMS can be only used for real emergency cases. This kind 
of practice can make the donor feel involved in a particular human action. A mobile phone 
application can be also used as a learning tool for children that sees it on their parent’s 
mobile. This will motivate them to donate blood when they reach the eligible age.  
Because of the high prevalence of some infectious diseases and because of the huge number 
of blood that can be discarded due to ineligibility leading to waste of financial resources, 
especially with some nationalities that are widely known to have a high prevalence of HCV, 
blood sample should be collected for HCV examination before collection of whole blood. 
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This practice can save a lot of money which can be used to improve the blood facility itself. 
Today is the ideal time to educate the students about the importance of blood donations. 
Schools should include in their curriculum the benefits of donating blood for health and 
how much this little effort can save thousands of lives, and faculty should be leaders in 
these practices. Undoubtedly, this will positively impact the donation practice by spreading 
awareness among the new generation.  
The BDC should put more efforts in the awareness part and advertisements through social 
media, websites, internet Pop-ups, direct mails, billboards, newspaper and TV. They should 
improve the official web site by providing more information as those proposed for the 
mobile application. Transfusion medicine clinicians should also conduct more education 
programs to direct physicians in performing correct practices when requesting blood and 
therefore avoid blood misuse or wastage. 
Finally, we highly recommend that the Component Processing Unit implement some 
validation on frozen packed RBCs in order to be able to use liquid blood in case of any 
emergency during the World Cup event and for daily routine needs as well.  
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